• Rhythm enters co-marketing agreement with leading breast cancer education non-profit
• Partnership to promote Rhythm's geneType Breast Cancer Risk Assessment Test
• Collaboration aligned with Breast Cancer Awareness Month in October

Rhythm Biosciences Ltd, an Australian innovative medical diagnostics company, has entered an important co-marketing relationship with the Know Your Lemons Foundation (KYL), a leading global non-profit organisation dedicated to breast cancer education and early detection. Under the agreement, Rhythm's geneType Breast Cancer Risk Assessment Test will now be actively promoted through the Know Your Lemons at Work breast health benefit employee community, reaching hundreds of thousands of women in the United States. While KYL has previously engaged with Genetic Technologies Limited to access geneType, Rhythm has now formalised and re-established the partnership under its stewardship and is actively collaborating on the rollout, which includes blogs, webinars and education to promote awareness and uptake of geneType. The collaboration represents an important step in Rhythm's commercialisation strategy, positioning geneType as a proactive tool in breast cancer risk assessment, complementing existing screening pathways. The partnership also aligns with Breast Cancer Awareness Month in October, a key opportunity to highlight the importance of early detection.Rhythm CEO David Atkins said the agreement accelerates the company's commercial activity with Know Your Lemons, allowing it to reach millions of women in the U.S. and Australia and support proactive health decisions and early detection outcomes. KYL Founder and CEO Corrine Ellsworth Beaumont said the incorporation of Rhythm's geneType test into the KYL app gives the community another valuable tool to understand and manage their breast cancer risk.

Rhythm Biosciences sees the partnership with Know Your Lemons as an important step in the commercialisation and brand awareness of its geneType Breast Cancer Risk Assessment Test, positioning it as a proactive tool for women to understand and manage their breast cancer risk.